Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Abstract Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models. Monotherapy with PD-1 inhibitors produced disappointing results, but combination...

Full description

Bibliographic Details
Main Authors: Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Hong Chang
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Journal of Hematology & Oncology
Subjects:
Immune checkpoint inhibitors
PD-L1
PD-1
Multiple myeloma
Histone deacetylase
Bromodomain and extraterminal inhibitors
Online Access:http://link.springer.com/article/10.1186/s13045-018-0589-1

Internet

http://link.springer.com/article/10.1186/s13045-018-0589-1

Similar Items